Taras Shevchenko National University of Kyiv, Kyiv, Ukraine.
UCLA/CURE West LA VA Medical Center, Los Angeles, California, United States of America.
PLoS One. 2019 Aug 22;14(8):e0220642. doi: 10.1371/journal.pone.0220642. eCollection 2019.
Epidemiological studies revealed that antibiotics exposure increases a risk of inflammatory bowel diseases (IBD) development. It remained largely unknown how antibiotic-induced dysbiosis confers the risk for enhanced inflammatory response. The aim of the present study was to test the hypothesis that SCFAs, their receptors and transporters mediate the antibiotic long-term effects on the functional state of colonic mucosa and susceptibility to the experimental colitis. Male Wistar rats were treated daily for 14 days with antibiotic ceftriaxone (300 mg/kg, i.m.) or vehicle; euthanized by CO2 inhalation followed by cervical dislocation in 1, 14 or 56 days after antibiotic withdrawal. We found increased cecum weight and sustained changes in microbiota composition after ceftriaxone treatment with increased number of conditionally pathogenic enterobacteria, E. coli, Clostridium, Staphylococcus spp. and hemolytic bacteria even at 56 days after antibiotic withdrawal. The concentration of SCFAs was decreased after ceftriaxone withdrawal. We found decreased immunoreactivity of the FFA2, FFA3 receptors, SMCT1 and increased MCT1 & MCT4 transporters of SCFAs in colon mucosa. These changes evoked a significant shift in colonic mucosal homeostasis: the disturbance of oxidant-antioxidant balance; activation of redox-sensitive transcription factor HIF1α and ERK1/2 MAP kinase; increased colonic epithelial permeability and bacterial translocation to blood; morphological remodeling of the colonic tissue. Ceftriaxone pretreatment significantly reinforced inflammation during experimental colitis 56 days after ceftriaxone withdrawal, which was confirmed by increased histopathology of colitis, Goblet cell dysfunction, colonic dilatation and wall thickening, and increased serum levels of inflammatory cytokines (TNF-α and IL-10). Since the recognition of the importance of microbiota metabolic activity rather than their composition in the development of inflammatory disorders, e.g. IBD, the present study is the first report on the role of the SCFA system in the long lasting side effects of antibiotic treatment and its implication in IBD development.
流行病学研究表明,抗生素暴露会增加炎症性肠病(IBD)的发病风险。抗生素诱导的肠道菌群失调如何增加炎症反应风险在很大程度上仍不清楚。本研究旨在检验以下假设:短链脂肪酸(SCFAs)及其受体和转运蛋白介导抗生素对结肠黏膜功能状态的长期影响及其对实验性结肠炎的易感性。雄性 Wistar 大鼠每天接受抗生素头孢曲松(300mg/kg,肌肉注射)或载体处理 14 天;在抗生素停药后 1、14 或 56 天,通过 CO2 吸入和颈椎脱位处死。我们发现,头孢曲松治疗后盲肠重量增加,微生物群落组成持续变化,条件致病菌肠杆菌、大肠杆菌、梭菌、葡萄球菌和溶血性细菌数量增加,甚至在抗生素停药后 56 天也是如此。头孢曲松停药后 SCFAs 浓度降低。我们发现结肠黏膜中 SCFAs 的 FFA2、FFA3 受体、SMCT1 免疫反应性降低,而 SCFAs 的 MCT1 和 MCT4 转运体增加。这些变化引起了结肠黏膜内稳态的显著变化:氧化还原平衡的紊乱;氧化还原敏感转录因子 HIF1α 和 ERK1/2 MAP 激酶的激活;结肠上皮通透性增加和细菌易位至血液;结肠组织的形态重塑。头孢曲松预处理在头孢曲松停药后 56 天的实验性结肠炎中显著增强了炎症,这通过增加结肠炎的组织病理学、杯状细胞功能障碍、结肠扩张和壁增厚以及炎症细胞因子(TNF-α和 IL-10)的血清水平得到证实。由于认识到微生物群代谢活性而不是其组成在炎症性疾病(例如 IBD)发展中的重要性,本研究首次报道了 SCFA 系统在抗生素治疗的长期副作用及其在 IBD 发展中的作用。